ストックスクリーナーアプリを入手
39.57
2.56%
-1.04
アフターアワーズ：
39.64
0.07
+0.18%
Sanofi Adr (SNY) 最新ニュース
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share - The Motley Fool
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Retension Pharmaceuticals Announces Pricing of Initial Public Offering - GlobeNewswire Inc.
Press Release : Availability of the aide-mémoire for Q3 2026 results - GlobeNewswire Inc.
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire » - GlobeNewswire Inc.
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
Full issuance would represent about 66.67% of Scinai (SCNI)'s depositary shares under its funding deal. - Stock Titan
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase - GlobeNewswire Inc.
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID - Finviz
RBC Capital initiates Sanofi stock at Sector Perform on transition risks - Investing.com Canada
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70%SNS Insider - GlobeNewswire Inc.
Sanofi ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - ad-hoc-news.de
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
European ADRs Drift Lower In US Trading - Finimize
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - morningstar.com
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Macau Business
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - tradingview.com
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi ADR earnings beat by $1.30, revenue topped estimates - investing.com
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews - GlobeNewswire Inc.
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire Inc.
0.10%
0.36%
大文字化:
|
ボリューム (24 時間):